- Home
- CATO vs QNCX Comparison
CATO vs QNCX Comparison
Compare CATO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- QNCX
- Stock Information
- Founded
- CATO 1946
- QNCX 2012
- Country
- CATO United States
- QNCX United States
- Employees
- CATO N/A
- QNCX N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CATO Consumer Discretionary
- QNCX Health Care
- Exchange
- CATO Nasdaq
- QNCX Nasdaq
- Market Cap
- CATO 59.2M
- QNCX 47.7M
- IPO Year
- CATO N/A
- QNCX 2019
- Fundamental
- Price
- CATO $2.81
- QNCX $1.93
- Analyst Decision
- CATO
- QNCX Strong Buy
- Analyst Count
- CATO 0
- QNCX 5
- Target Price
- CATO N/A
- QNCX $8.00
- AVG Volume (30 Days)
- CATO 34.4K
- QNCX 267.4K
- Earning Date
- CATO 08-21-2025
- QNCX 08-12-2025
- Dividend Yield
- CATO 6.05%
- QNCX N/A
- EPS Growth
- CATO N/A
- QNCX N/A
- EPS
- CATO N/A
- QNCX N/A
- Revenue
- CATO $642,949,000.00
- QNCX N/A
- Revenue This Year
- CATO N/A
- QNCX N/A
- Revenue Next Year
- CATO N/A
- QNCX N/A
- P/E Ratio
- CATO N/A
- QNCX N/A
- Revenue Growth
- CATO N/A
- QNCX N/A
- 52 Week Low
- CATO $2.19
- QNCX $0.51
- 52 Week High
- CATO $6.70
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CATO 46.89
- QNCX 64.07
- Support Level
- CATO $2.79
- QNCX $1.65
- Resistance Level
- CATO $3.07
- QNCX $1.83
- Average True Range (ATR)
- CATO 0.18
- QNCX 0.15
- MACD
- CATO -0.02
- QNCX 0.00
- Stochastic Oscillator
- CATO 16.67
- QNCX 54.39
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.